Summary

Global Amphotericin B market was valued at USD 69.41 million in 2024 and is projected to reach USD 105.54 million by 2030, growing at a compound annual growth rate (CAGR) of 2.91% during the forecast period. The market is experiencing consistent growth, primarily driven by the rising incidence of life-threatening fungal infections and the expanding population of immunocompromised individuals worldwide. Amphotericin B, a polyene antifungal agent, remains one of the most effective treatments for severe systemic mycoses, including cryptococcal meningitis, aspergillosis, mucormycosis, and candidiasis. Despite the emergence of newer antifungal agents, Amphotericin B continues to maintain significant therapeutic relevance, especially in hospital settings and in cases of multidrug resistance. A key factor contributing to the market's growth is the increasing prevalence of opportunistic fungal infections among immunocompromised patients, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. The rise in mucormycosis cases, particularly during the COVID-19 pandemic in certain regions, has further heightened the demand for Amphotericin B. Moreover, advancements in liposomal and lipid complex formulations have improved drug tolerability and reduced nephrotoxicity, further enhancing clinical adoption. Expanding healthcare access and growing awareness in developing economies are also driving greater use of antifungal therapies, thereby enhancing market potential.
Key Market Drivers
Growth in Healthcare Industry:
The continued expansion of the global healthcare sector is a major driver of the Amphotericin B market. The global hospital market is expected to generate USD 4.41 trillion in revenue by 2025. In the United States, hospitals are making significant investments in telemedicine to extend remote healthcare services, particularly in rural areas. As healthcare systems evolve and infrastructure improves in both developed and emerging economies, there is a growing emphasis on effective treatments for life-threatening fungal infections, where Amphotericin B remains a gold standard. Known for its potent antifungal properties, Amphotericin B is widely used in managing systemic mycoses, particularly in immunocompromised patients such as those with HIV/AIDS, cancer, or undergoing organ transplants.
Key Market Challenges
Toxicity and Adverse Side Effects:
A significant challenge facing the global Amphotericin B market is the drug's known toxicity and adverse side effects. Although Amphotericin B is considered a gold standard for treating severe fungal infections, its use is often limited by safety concerns, particularly nephrotoxicity, which can lead to acute kidney injury in a significant proportion of patients. Other common adverse effects include infusion-related reactions such as fever, chills, hypotension, and electrolyte imbalances. These side effects require intensive monitoring and hospitalization, thus increasing treatment costs and complexity. While liposomal and lipid-based formulations have helped mitigate some of these toxicities, their high cost limits broader adoption, particularly in resource-limited settings. The ongoing challenge of balancing efficacy with safety remains a major concern for healthcare providers and pharmaceutical manufacturers, highlighting the need for safer, equally effective alternatives or improved formulations in the antifungal therapeutics market.
Key Market Trends
Increasing Prevalence of Fungal Infections:
The rising global incidence of fungal infections has become a defining trend in the growth of the Amphotericin B market. It is estimated that invasive fungal infections occur at a rate of approximately 6.5 million cases annually, leading to around 3.8 million deaths. Of these, an estimated 2.5 million fatalities—representing 68% (ranging between 35% and 90%)—are directly caused by these infections. Invasive aspergillosis alone affects over 2.1 million individuals annually, primarily among patients with chronic obstructive pulmonary disease (COPD), those in intensive care units, and individuals with hematologic malignancies or lung cancer. This condition has a concerning mortality rate of 85.2%. With the growing number of individuals affected by opportunistic and invasive fungal diseases, the demand for potent antifungal therapies such as Amphotericin B has significantly increased.
Key Market Players
• Xiamen Neore Pharmaceutical Technology Co., Ltd
• Concord Biotech Limited
• United Biotech Pvt Ltd
• Hubei Aoks Bio-Tech Co.,Ltd
• Synbiotics Limited
• North China Pharmaceutical Huasheng Co., Ltd
• Xi'an Sonwu Biotech Co., Ltd.
• Century Pharmaceutical Ltd
• Xellia Pharmaceuticals
Report Scope
In this report, the Global Amphotericin B Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Amphotericin B Market, By Sales Channel:
o Direct
o Indirect
• Amphotericin B Market, By End Use:
o Systemic Fungal Infections
o Candidiasis
o Aspergillosis
o Mucormycosis
o Leishmaniasis
o Others
• Amphotericin B Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Amphotericin B Market.
Available Customizations:
Global Amphotericin B Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Amphotericin B Market
5. Global Amphotericin B Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Sales Channel (Direct, Indirect)
5.2.2. By End Use (Systemic Fungal Infections, Candidiasis, Aspergillosis, Mucormycosis, Leishmaniasis, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Amphotericin B Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Sales Channel
6.2.2. By End Use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Amphotericin B Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Sales Channel
6.3.1.2.2. By End Use
6.3.2. Mexico Amphotericin B Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Sales Channel
6.3.2.2.2. By End Use
6.3.3. Canada Amphotericin B Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Sales Channel
6.3.3.2.2. By End Use
7. Europe Amphotericin B Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Sales Channel
7.2.2. By End Use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Amphotericin B Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Sales Channel
7.3.1.2.2. By End Use
7.3.2. Germany Amphotericin B Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Sales Channel
7.3.2.2.2. By End Use
7.3.3. United Kingdom Amphotericin B Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Sales Channel
7.3.3.2.2. By End Use
7.3.4. Italy Amphotericin B Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Sales Channel
7.3.4.2.2. By End Use
7.3.5. Spain Amphotericin B Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Sales Channel
7.3.5.2.2. By End Use
8. Asia Pacific Amphotericin B Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Sales Channel
8.2.2. By End Use
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Amphotericin B Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Sales Channel
8.3.1.2.2. By End Use
8.3.2. India Amphotericin B Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Sales Channel
8.3.2.2.2. By End Use
8.3.3. South Korea Amphotericin B Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Sales Channel
8.3.3.2.2. By End Use
8.3.4. Japan Amphotericin B Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Sales Channel
8.3.4.2.2. By End Use
8.3.5. Australia Amphotericin B Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Sales Channel
8.3.5.2.2. By End Use
9. South America Amphotericin B Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Sales Channel
9.2.2. By End Use
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Amphotericin B Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Sales Channel
9.3.1.2.2. By End Use
9.3.2. Argentina Amphotericin B Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Sales Channel
9.3.2.2.2. By End Use
9.3.3. Colombia Amphotericin B Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Sales Channel
9.3.3.2.2. By End Use
10. Middle East and Africa Amphotericin B Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Sales Channel
10.2.2. By End Use
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Amphotericin B Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Sales Channel
10.3.1.2.2. By End Use
10.3.2. Saudi Arabia Amphotericin B Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Sales Channel
10.3.2.2.2. By End Use
10.3.3. UAE Amphotericin B Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Sales Channel
10.3.3.2.2. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Amphotericin B Market: SWOT Analysis
14. Porters Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Xiamen Neore Pharmaceutical Technology Co., Ltd
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Concord Biotech Limited
15.3. United Biotech Pvt Ltd
15.4. Hubei Aoks Bio-Tech Co.,Ltd
15.5. Synbiotics Limited
15.6. North China Pharmaceutical Huasheng Co., Ltd
15.7. Xi'an Sonwu Biotech Co., Ltd.
15.8. Century Pharmaceutical Ltd
15.9. Xellia Pharmaceuticals
16. Strategic Recommendations
17. About Us & Disclaimer